Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from…
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases,…
November 28, 2025 20:13 ET | Source: Rakovina Therapeutics Inc VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina…
November 28, 2025 08:00 ET | Source: Spero Therapeutics, Inc. CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics,…
BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on…
November 18, 2025 16:30 ET | Source: Protara Therapeutics NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.…
CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (Nasdaq:LPTX), a company developing novel…
Khing Oei appointed Chairman of the Board; Will McEvoy appointed Chief Investment Officer and Member of the Board; Cypherpunk Technologies…
Sanjeev Luther, President and CEO to give an oral presentation and participate in a moderated panel discussion November 11, 2025…
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic responses – - A novel mechanism…